AR112265A1 - Antagonista del receptor de angiotensina ii para la prevención o tratamiento de enfermedades sistémicas en gatos - Google Patents
Antagonista del receptor de angiotensina ii para la prevención o tratamiento de enfermedades sistémicas en gatosInfo
- Publication number
- AR112265A1 AR112265A1 ARP180101883A AR112265A1 AR 112265 A1 AR112265 A1 AR 112265A1 AR P180101883 A ARP180101883 A AR P180101883A AR 112265 A1 AR112265 A1 AR 112265A1
- Authority
- AR
- Argentina
- Prior art keywords
- treatment
- sartan
- angiotensin
- amount
- prophylaxis
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title abstract 8
- 239000002333 angiotensin II receptor antagonist Substances 0.000 title abstract 2
- 229940126317 angiotensin II receptor antagonist Drugs 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 230000009885 systemic effect Effects 0.000 title 1
- 241000282326 Felis catus Species 0.000 abstract 3
- 238000011321 prophylaxis Methods 0.000 abstract 3
- 102000008873 Angiotensin II receptor Human genes 0.000 abstract 2
- 108050000824 Angiotensin II receptor Proteins 0.000 abstract 2
- 206010020772 Hypertension Diseases 0.000 abstract 2
- 239000005557 antagonist Substances 0.000 abstract 2
- 239000012669 liquid formulation Substances 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 230000037396 body weight Effects 0.000 abstract 1
- 239000000969 carrier Substances 0.000 abstract 1
- 230000007423 decrease Effects 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
Abstract
Reivindicación 1: Un antagonista del receptor 1 de angiotensina II (AT-1) (sartan) para usar en un método para la profilaxis o tratamiento de hipertensión en un gato que necesita tal profilaxis o tratamiento, caracterizado porque el método comprende la administración de una cantidad terapéuticamente efectiva del antagonista del receptor 1 de angiotensina II (AT-1) (sartan) al gato, donde la cantidad terapéuticamente efectiva del sartan se administra en una cantidad de dosis diaria que varia durante un periodo de tratamiento, la cantidad de dosis diaria del sartan durante un primer periodo de tiempo durante el periodo de tratamiento es 1,0 a 5,0 mg/kg de peso corporal, y la cantidad de dosis diaria del sartan disminuye durante un segundo periodo de tiempo posterior al primer período de tiempo durante el periodo de tratamiento. Reivindicación 16: Un kit en partes caracterizado porque comprende: un contenedor que contiene una composición farmacéutica en una formulación líquida que comprende un antagonista del receptor de angiotensina II (AT-1) (sartan) y uno o más diluyentes y/o portadores farmacéuticamente aceptables, la cantidad de sartan que está dentro de la formulación líquida en una cantidad que es terapéuticamente efectiva para la profilaxis o el tratamiento de la hipertensión en un gato que necesita de tal tratamiento; y una jeringa que comprende un cilindro y opcionalmente tiene marcas de graduación volumétricas opcionalmente impresas en esta en incrementos de 0,25 ml o menos o en incrementos de 0,10 ml o menos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762529587P | 2017-07-07 | 2017-07-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR112265A1 true AR112265A1 (es) | 2019-10-09 |
Family
ID=62904440
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP180101883 AR112265A1 (es) | 2017-07-07 | 2018-07-05 | Antagonista del receptor de angiotensina ii para la prevención o tratamiento de enfermedades sistémicas en gatos |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US10905676B2 (es) |
| EP (2) | EP4299120A3 (es) |
| JP (2) | JP7050893B2 (es) |
| KR (3) | KR20250007040A (es) |
| CN (1) | CN110785168A (es) |
| AR (1) | AR112265A1 (es) |
| AU (1) | AU2018295387B2 (es) |
| BR (1) | BR112020000194A2 (es) |
| CA (1) | CA3067918A1 (es) |
| DK (1) | DK3648761T3 (es) |
| EA (1) | EA202090205A1 (es) |
| ES (1) | ES2979279T3 (es) |
| FI (1) | FI3648761T3 (es) |
| HR (1) | HRP20240703T1 (es) |
| HU (1) | HUE067255T2 (es) |
| LT (1) | LT3648761T (es) |
| NZ (1) | NZ759782A (es) |
| PL (1) | PL3648761T3 (es) |
| PT (1) | PT3648761T (es) |
| RS (1) | RS65570B1 (es) |
| SI (1) | SI3648761T1 (es) |
| TW (1) | TW201919703A (es) |
| WO (1) | WO2019008077A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3142877A1 (en) | 2019-07-09 | 2021-01-14 | Boehringer Ingelheim Vetmedica Gmbh | Telmisartan for the treatment of chronic kidney disease in dogs |
| CA3142876A1 (en) | 2019-07-09 | 2021-01-14 | Boehringer Ingelheim Vetmedica Gmbh | Telmisartan for the treatment of chronic kidney disease in dogs |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5671074A (en) | 1979-11-12 | 1981-06-13 | Takeda Chem Ind Ltd | 1,2-disubstituted-4-halogenoimidazole-5-acetic acid derivative |
| CA1334092C (en) | 1986-07-11 | 1995-01-24 | David John Carini | Angiotensin ii receptor blocking imidazoles |
| US5015651A (en) | 1988-01-07 | 1991-05-14 | E. I. Du Pont De Nemours And Company | Treatment of hypertension with 1,2,4-angiotensin II antagonists |
| CA1338238C (en) | 1988-01-07 | 1996-04-09 | David John Carini | Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids |
| US4880804A (en) | 1988-01-07 | 1989-11-14 | E. I. Du Pont De Nemours And Company | Angiotensin II receptor blocking benzimidazoles |
| IE70593B1 (en) | 1989-09-29 | 1996-12-11 | Eisai Co Ltd | Biphenylmethane derivative the use of it and pharmacological compositions containing same |
| PH30484A (en) | 1990-02-19 | 1997-05-28 | Ciba Geigy | Acy compounds pharmaceutical composition containing said compound and method of use thereof |
| IE910913A1 (en) | 1990-03-20 | 1991-09-25 | Sanofi Sa | N-substituted heterocyclic derivates, their preparation¹and pharmaceutical compositions containing them |
| US5196444A (en) | 1990-04-27 | 1993-03-23 | Takeda Chemical Industries, Ltd. | 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof |
| IL99246A0 (en) | 1990-09-10 | 1992-07-15 | Abbott Lab | Angiotensin ii receptor antagonists and pharmaceutical compositions containing them |
| GB9027210D0 (en) | 1990-12-14 | 1991-02-06 | Smithkline Beecham Plc | Medicaments |
| US6028091A (en) | 1990-12-14 | 2000-02-22 | Smithkline Beecham Plc | Medicament |
| SI9210098B (sl) | 1991-02-06 | 2000-06-30 | Dr. Karl Thomae | Benzimidazoli, zdravila, ki te spojine vsebujejo, in postopek za njihovo pripravo |
| US5196537A (en) | 1991-03-21 | 1993-03-23 | G. D. Searle & Co. | 5-apylheteroarylalkyl-1,3,5-trisubstituted-1,2,4-triazole compounds for treatment of circulatory disorders |
| GB9110636D0 (en) | 1991-05-16 | 1991-07-03 | Glaxo Group Ltd | Chemical compounds |
| DE69325574T2 (de) | 1992-04-13 | 2000-03-16 | Zeneca Ltd. | ANGIOTENSIN-II-ANTAGONISTEN GEGEN ERKRANKUNGEN; DIE MIT EINER EINGESCHRäNKTEN; NEURONALEN LEITUNGSGESCHWINDIGKEIT VERBUNDEN SIND, INSBESONDERE DIABETISCHE NEUROPATHIE |
| EP0754042A4 (en) | 1994-03-29 | 2004-06-23 | Merck & Co Inc | TREATING ATHEROSCLEROSIS WITH IMIDAZOLES BLOCKING THE ANGIOTENSIN II RECEPTOR |
| DE19901921C2 (de) | 1999-01-19 | 2001-01-04 | Boehringer Ingelheim Pharma | Polymorphe von Telmisartan, Verfahren zu deren Herstellung und deren Verwendung zur Herstellung eines Arzneimittels |
| US6358986B1 (en) | 1999-01-19 | 2002-03-19 | Boehringer Ingelheim Pharma Kg | Polymorphs of telmisartan |
| DE10018401A1 (de) | 2000-04-13 | 2001-10-25 | Boehringer Ingelheim Pharma | Verwendung von Bradycardica bei der Behandlung von mit Hypertrophie einhergehenden Myocarderkrankungen und neue Arzneimittelkombinationen |
| WO2002092081A1 (en) | 2001-05-14 | 2002-11-21 | Merck & Co., Inc. | Method of treatment |
| DE10153737A1 (de) | 2001-10-31 | 2003-05-28 | Boehringer Ingelheim Pharma | Kristallines Natriumsalz des Telmisartans, Verfahren zu dessen Herstellung und dessen Verwendung zur Herstellung eines Arzneimittels |
| US8980870B2 (en) | 2002-09-24 | 2015-03-17 | Boehringer Ingelheim International Gmbh | Solid telmisartan pharmaceutical formulations |
| EP1579862A1 (en) | 2004-03-25 | 2005-09-28 | Boehringer Ingelheim Vetmedica Gmbh | Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure |
| US20070026026A1 (en) | 2005-08-01 | 2007-02-01 | David Delmarre | Oral liquid losartan compositions |
| EP1908469A1 (en) | 2006-10-06 | 2008-04-09 | Boehringer Ingelheim Vetmedica Gmbh | Angiotensin II receptor antagonist for the treatment of systemic diseases in cats |
| CA2653011A1 (en) * | 2008-12-03 | 2010-06-03 | Apotex Technologies Inc | Method and apparatus for packaging and dispensing pharmaceuticals |
| SG176585A1 (en) * | 2009-05-20 | 2012-01-30 | Boehringer Ingelheim Vetmed | Pharmaceutical oral telmisartan solution |
| WO2016200694A1 (en) * | 2015-06-10 | 2016-12-15 | Hackensack University Medical Center | Use of telmisartan to prevent and treat graft versus host disease and other alloimmune and autoimmune diseases |
| JP2019526641A (ja) | 2016-09-07 | 2019-09-19 | ソニオナ エー／エス | テソフェンシン組成物 |
-
2018
- 2018-07-05 KR KR1020247042412A patent/KR20250007040A/ko active Pending
- 2018-07-05 PT PT187401534T patent/PT3648761T/pt unknown
- 2018-07-05 FI FIEP18740153.4T patent/FI3648761T3/fi active
- 2018-07-05 EP EP23204038.6A patent/EP4299120A3/en active Pending
- 2018-07-05 DK DK18740153.4T patent/DK3648761T3/da active
- 2018-07-05 TW TW107123267A patent/TW201919703A/zh unknown
- 2018-07-05 ES ES18740153T patent/ES2979279T3/es active Active
- 2018-07-05 AR ARP180101883 patent/AR112265A1/es unknown
- 2018-07-05 CN CN201880033892.1A patent/CN110785168A/zh active Pending
- 2018-07-05 EA EA202090205A patent/EA202090205A1/ru unknown
- 2018-07-05 WO PCT/EP2018/068189 patent/WO2019008077A1/en active Application Filing
- 2018-07-05 JP JP2020500145A patent/JP7050893B2/ja active Active
- 2018-07-05 RS RS20240617A patent/RS65570B1/sr unknown
- 2018-07-05 SI SI201831100T patent/SI3648761T1/sl unknown
- 2018-07-05 LT LTEPPCT/EP2018/068189T patent/LT3648761T/lt unknown
- 2018-07-05 HR HRP20240703TT patent/HRP20240703T1/hr unknown
- 2018-07-05 BR BR112020000194-5A patent/BR112020000194A2/pt active Search and Examination
- 2018-07-05 AU AU2018295387A patent/AU2018295387B2/en active Active
- 2018-07-05 PL PL18740153.4T patent/PL3648761T3/pl unknown
- 2018-07-05 KR KR1020207003639A patent/KR20200026975A/ko not_active IP Right Cessation
- 2018-07-05 CA CA3067918A patent/CA3067918A1/en active Pending
- 2018-07-05 HU HUE18740153A patent/HUE067255T2/hu unknown
- 2018-07-05 NZ NZ759782A patent/NZ759782A/en unknown
- 2018-07-05 KR KR1020237039620A patent/KR20230161541A/ko not_active Ceased
- 2018-07-05 EP EP18740153.4A patent/EP3648761B1/en active Active
- 2018-07-05 US US16/027,422 patent/US10905676B2/en active Active
-
2020
- 2020-12-22 US US17/131,312 patent/US20210106564A1/en active Pending
-
2022
- 2022-02-18 JP JP2022023799A patent/JP7402907B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| PL3648761T3 (pl) | 2024-07-22 |
| KR20250007040A (ko) | 2025-01-13 |
| JP7402907B2 (ja) | 2023-12-21 |
| JP2020526516A (ja) | 2020-08-31 |
| BR112020000194A2 (pt) | 2020-07-07 |
| DK3648761T3 (da) | 2024-06-24 |
| EP3648761A1 (en) | 2020-05-13 |
| RS65570B1 (sr) | 2024-06-28 |
| AU2018295387A1 (en) | 2020-01-02 |
| EA202090205A1 (ru) | 2020-06-02 |
| HUE067255T2 (hu) | 2024-10-28 |
| TW201919703A (zh) | 2019-06-01 |
| CN110785168A (zh) | 2020-02-11 |
| SI3648761T1 (sl) | 2024-07-31 |
| CA3067918A1 (en) | 2019-01-10 |
| US20210106564A1 (en) | 2021-04-15 |
| ES2979279T3 (es) | 2024-09-25 |
| LT3648761T (lt) | 2024-06-10 |
| KR20200026975A (ko) | 2020-03-11 |
| US20190008831A1 (en) | 2019-01-10 |
| PT3648761T (pt) | 2024-06-05 |
| EP3648761B1 (en) | 2024-03-13 |
| JP7050893B2 (ja) | 2022-04-08 |
| US10905676B2 (en) | 2021-02-02 |
| AU2018295387B2 (en) | 2024-02-15 |
| NZ759782A (en) | 2023-06-30 |
| HRP20240703T1 (hr) | 2024-08-16 |
| WO2019008077A1 (en) | 2019-01-10 |
| EP4299120A2 (en) | 2024-01-03 |
| FI3648761T3 (fi) | 2024-05-21 |
| KR20230161541A (ko) | 2023-11-27 |
| JP2022075670A (ja) | 2022-05-18 |
| EP4299120A3 (en) | 2024-03-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2508290T3 (es) | Composición farmacéutica para la administracón de compuestos de inhibición del receptor de tirosina cinasa (RTKI) al ojo | |
| PE20210401A1 (es) | Composiciones farmaceuticas que comprenden meloxicam | |
| HRP20240485T1 (hr) | Pripravci glp-1 i njihova upotreba | |
| FI3735295T3 (fi) | Parannetut peptidilääkkeet nashin ja muiden sairauksien hoitoon | |
| PH12015502691A1 (en) | Use of high dose pridopidine for treating huntington's disease | |
| MX2019001596A (es) | Uso y dosificacion de agentes terapeuticos para endometriosis. | |
| JP2016512564A5 (es) | ||
| AR112265A1 (es) | Antagonista del receptor de angiotensina ii para la prevención o tratamiento de enfermedades sistémicas en gatos | |
| JP2019530706A5 (es) | ||
| CO2021007186A2 (es) | Composición farmacéutica para el tratamiento de la hipertensión arterial pulmonar | |
| AR043259A1 (es) | Metodo para el tratamiento de insuficiencia cardiaca severa y medicamento para ello | |
| CL2019003533A1 (es) | Uso de vibegron para tratar vejiga sobreactiva. | |
| CY1124236T1 (el) | Διαλυμα εγχυσης λεβοντοπα | |
| BR112022020933A2 (pt) | Inibidores de replicação do vírus da imunodeficiência humana | |
| HRP20240812T1 (hr) | Oblici doziranja i terapijska primjena l-4-klorokinurenina | |
| AR065139A1 (es) | Medicamento para el tratamiento de la endometriosis | |
| Mejía-Chew et al. | Resolution of massive tophaceous gout with three urate-lowering drugs | |
| MX2023005295A (es) | Tratamiento contra el cancer resistente a platino. | |
| RU2015119223A (ru) | Система дозированного распределения | |
| AR068531A1 (es) | Dosis fija por inyeccion unica para ocrelizumab (2h7). uso de rituximab. formulacion farmaceutica. kit. | |
| CL2021001933A1 (es) | Composición farmacéutica que comprende macitentán para el tratamiento de la hipertensión pulmonar tromboembólica crónica. | |
| PE20130782A1 (es) | Composiciones farmaceuticas que consisten de paracetamol y el proceso para la preparacion del mismo | |
| MX2018005298A (es) | Regimen de dosificacion para un inhibidor de fosfatidilinositol 3-quinasa. | |
| JP2016538295A5 (es) | ||
| PE20040706A1 (es) | Derivado especifico de amina ciclica y sus sales farmaceuticamente aceptables involucrados en la prevencion de la insuficiencia cardiaca |